Compare Illumina, Inc. (ILMN) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Msci Inc — how do they compare? Illumina, Inc. trades at $189.68 (market cap $27.94B), while Msci Inc trades at $570.05 (market cap $45.51B). The key difference: Msci Inc is the larger of the two by market cap, and Msci Inc pays a 1.31% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | MSCI | |
|---|---|---|
Market Cap | $27.94B | $45.51B |
Sector | Health | Financials |
52-Week High | $194.33 | $643.83 |
52-Week Low | $91.00 | $511.84 |
Enterprise Value | $29.33B | $51.67B |
Dividend Yield | — | 1.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
MSCI trades at $625.11, down 0.56% on the day, with a bullish technical outlook supported by moving averages and a recent strategic partnership with UBS to enhance its private markets platform. The company shows strong fundamentals with a 40.74% net income margin and consistent earnings beats, though valuation ratios like a P/E of 35.9 suggest a premium. Analyst consensus is strongly bullish with a $723.38 price target, and cash flow turned positive in 2025 after prior years of net outflows.
The outlook for MSCI is positive, driven by earnings growth, high profitability, and strategic expansions, but risks include elevated debt levels and sensitivity to financial market conditions. The stock offers a dividend yield supported by solid cash generation, though investors should weigh the high valuation against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
